These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24178577)

  • 1. Molecular alterations and biomarkers in colorectal cancer.
    Grady WM; Pritchard CC
    Toxicol Pathol; 2014 Jan; 42(1):124-39. PubMed ID: 24178577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
    Lupini L; Bassi C; Mlcochova J; Musa G; Russo M; Vychytilova-Faltejskova P; Svoboda M; Sabbioni S; Nemecek R; Slaby O; Negrini M
    BMC Cancer; 2015 Oct; 15():808. PubMed ID: 26508446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.
    Musella V; Pietrantonio F; Di Buduo E; Iacovelli R; Martinetti A; Sottotetti E; Bossi I; Maggi C; Di Bartolomeo M; de Braud F; Daidone MG; Cappelletti V
    Int J Cancer; 2015 Sep; 137(6):1467-74. PubMed ID: 25704501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.
    Esposito C; Rachiglio AM; La Porta ML; Sacco A; Roma C; Iannaccone A; Tatangelo F; Forgione L; Pasquale R; Barbaro A; Botti G; Ciardiello F; Normanno N
    Cancer Biol Ther; 2013 Dec; 14(12):1143-6. PubMed ID: 24025416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
    Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
    Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer molecular biology moves into clinical practice.
    Pritchard CC; Grady WM
    Gut; 2011 Jan; 60(1):116-29. PubMed ID: 20921207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
    Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A
    Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
    Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
    Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
    Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
    Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS testing and its importance in colorectal cancer.
    Patil DT; Fraser CR; Plesec TP
    Curr Oncol Rep; 2010 May; 12(3):160-7. PubMed ID: 20425075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
    Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.